Tanvex BioPharma, Inc.
Taiwan Stock ExchangeTotal Valuation
Tanvex BioPharma, Inc. carries a market capitalization of 10.94B, placing it among publicly traded companies globally. Its enterprise value stands at 13.82B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 10.94B |
| Enterprise Value | 13.82B |
Share Statistics
Tanvex BioPharma, Inc. currently has 264.86M shares outstanding.
| Shares Outstanding | 264.86M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 32.73, and the price-to-book ratio stands at -1.01.
| PE Ratio | N/A |
| PS Ratio | 32.73 |
| PB Ratio | -1.01 |
| P/TBV Ratio | 5.71 |
| P/FCF Ratio | -39.15 |
| P/OCF Ratio | -13.05 |
Enterprise Valuation
| EV / Sales | 34.48 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Tanvex BioPharma, Inc. maintains a current ratio of 1.87, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 27.72, indicating elevated leverage, while an interest coverage ratio of -29.26 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.87 |
| Quick Ratio | 1.10 |
| Debt / Equity | 27.72 |
| Debt / EBITDA | -1.14 |
| Interest Coverage | -29.26 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -28.05 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.65 |
Taxes
| Income Tax | -3.05M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Tanvex BioPharma, Inc.'s stock has declined approximately -19.44607% over the past 52 weeks. The 50-day moving average sits at 40.05, while the 200-day moving average is 48.41.
| Beta (5Y) | N/A |
| 52-Week Price Change | -19.44607% |
| 50-Day Moving Average | 40.05 |
| 200-Day Moving Average | 48.41 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Tanvex BioPharma, Inc. generated 400.97M in revenue and converted that into -1.50B in net income, yielding earnings per share of -6.29. EBITDA reached -1.38B, while operating income came in at -1.38B.
| Revenue | 400.97M |
| Gross Profit | -440.71M |
| Operating Income | -1.38B |
| Pretax Income | -1.50B |
| Net Income | -1.50B |
| EBITDA | -1.38B |
| EBIT | -1.38B |
| Earnings Per Share (EPS) | -6.29 |
Balance Sheet
Tanvex BioPharma, Inc. holds 878.71M in cash and equivalents against 1.58B in total debt, resulting in a net debt position of -848.71M. Total book value stands at -12.99B, with working capital of 697.52M providing operational flexibility.
| Cash & Cash Equivalents | 878.71M |
| Total Debt | 1.58B |
| Net Debt | -848.71M |
| Equity (Book Value) | -12.99B |
| Book Value Per Share | -54.43 |
| Working Capital | 697.52M |
Cash Flow
Tanvex BioPharma, Inc. produced -1.01B in operating cash flow over the past twelve months. After subtracting -670.20M in capital expenditures, free cash flow totaled -1.68B - equivalent to -7.02 per share.
| Operating Cash Flow | -1.01B |
| Capital Expenditures | -670.20M |
| Free Cash Flow | -1.68B |
| FCF Per Share | -7.02 |
Margins
Tanvex BioPharma, Inc. operates with a gross margin of -109.91, reflecting its pricing power and cost economics. The operating margin of -344.59 and net profit margin of -374.13 provide insight into operational efficiency.
| Gross Margin | -109.91 |
| Operating Margin | -344.59 |
| Pretax Margin | -374.89 |
| Profit Margin | -374.13 |
| EBITDA Margin | -344.59 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -8.67 |
| FCF Yield | -2.55 |
Stock Splits
Tanvex BioPharma, Inc.'s most recent stock split took place on March 2, 2023 with a 1000:333 split ratio.
| Last Split Date | 3/2/2023 |
| Split Ratio | 1000:333 |
Scores
Tanvex BioPharma, Inc. posts an Altman Z-Score of -2.05, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -2.05 |